- Home
- ISOU vs PROK Comparison
ISOU vs PROK Comparison
Compare ISOU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISOU
- PROK
- Stock Information
- Founded
- ISOU 2016
- PROK 2015
- Country
- ISOU Canada
- PROK United States
- Employees
- ISOU N/A
- PROK N/A
- Industry
- ISOU
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISOU
- PROK Health Care
- Exchange
- ISOU Nasdaq
- PROK Nasdaq
- Market Cap
- ISOU 357.6M
- PROK 384.2M
- IPO Year
- ISOU N/A
- PROK N/A
- Fundamental
- Price
- ISOU $7.61
- PROK $2.35
- Analyst Decision
- ISOU
- PROK Buy
- Analyst Count
- ISOU 0
- PROK 5
- Target Price
- ISOU N/A
- PROK $6.25
- AVG Volume (30 Days)
- ISOU 51.9K
- PROK 3.3M
- Earning Date
- ISOU 05-12-2025
- PROK 08-12-2025
- Dividend Yield
- ISOU N/A
- PROK N/A
- EPS Growth
- ISOU N/A
- PROK N/A
- EPS
- ISOU N/A
- PROK N/A
- Revenue
- ISOU N/A
- PROK $527,000.00
- Revenue This Year
- ISOU N/A
- PROK $105.79
- Revenue Next Year
- ISOU N/A
- PROK N/A
- P/E Ratio
- ISOU N/A
- PROK N/A
- Revenue Growth
- ISOU N/A
- PROK N/A
- 52 Week Low
- ISOU $5.72
- PROK $0.46
- 52 Week High
- ISOU $8.64
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- ISOU N/A
- PROK 43.77
- Support Level
- ISOU N/A
- PROK $2.16
- Resistance Level
- ISOU N/A
- PROK $2.46
- Average True Range (ATR)
- ISOU 0.00
- PROK 0.34
- MACD
- ISOU 0.00
- PROK -0.16
- Stochastic Oscillator
- ISOU 0.00
- PROK 7.14
About ISOU IsoEnergy Ltd. Common Shares
IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Thorburn Lake, Radio, Geiger, and Larocque East. and others. It operates in Canada, the United States, and Australia.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.